Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

PrEP science news

Show

From To
Increase in STIs in PrEP users is concentrated in a minority of men and is partly due to more STI screening

There were significant increases in bacterial sexually transmitted infections (STIs) in gay and bisexual men taking pre-exposure prophylaxis (PrEP) for the first time in Victoria, Australia, but

Published
01 August 2018
By
Roger Pebody
Unprecedented hepatitis C infection rates seen in gay men in Amsterdam PrEP programme

Regular hepatitis C testing among the HIV-negative gay men and other men who have sex with men (MSM) participating in the Amsterdam pre-exposure prophylaxis (PrEP)

Published
25 July 2018
By
Gus Cairns
PrEP does not lower feminising hormone level in transgender women

Using Truvada (tenofovir DF/emtricitabine) for HIV prevention does not lower levels of feminising hormones, offering reassurance for transgender women who are concerned about drug interactions, according to a

Published
25 July 2018
By
Liz Highleyman
‘Risky when young’ or ‘risky with age’: Dutch study identifies life patterns associated with higher HIV risk in gay men

A Dutch study which looked at the way gay men’s risk of HIV changed with time has used statistical analysis to isolate two kinds of

Published
25 May 2018
By
Gus Cairns
PrEP may make it hard to tell if someone has an HIV infection

It may be very difficult to tell if someone who has just started HIV pre-exposure prophylaxis (PrEP) has actually caught HIV just before or just

Published
23 May 2018
By
Gus Cairns
Age difference in HIV infection matters – but it’s not always the younger person who is at risk

A European study of men who have sex with men (MSM) presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2018) shows that age

Published
19 March 2018
By
Gus Cairns
Powerful new PrEP and treatment drug should be effective as a small weekly pill

MK-8591 or EFdA is a novel and exceptionally long-lasting and potent HIV drug, being developed by Merck. It is a nucleoside reverse transcriptase translocation inhibitor

Published
12 March 2018
By
Gus Cairns
How much 'PrEP-resistant' HIV is out there?

A study presented at the recent 25th Conference on Retroviruses and Opportunistic Infections (CROI 2018) aims to quantify how many people with HIV there might be

Published
09 March 2018
By
Gus Cairns
Study finds that women are much more vulnerable to HIV infection during pregnancy and in the months after giving birth

A study presented today at the Conference on Retroviruses and Opportunistic Infections (CROI 2018) found that women in two prevention studies were nearly three times more likely

Published
05 March 2018
By
Gus Cairns
PrEP does not raise lipids or alter body fat, safety study finds

Using pre-exposure prophylaxis (PrEP) does not raise lipid levels or have any substantial effect on body fat, investigators from the iPrEX trial report this month

Published
15 February 2018
By
Keith Alcorn

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.